Market Cap 204.48B
Revenue (ttm) 36.75B
Net Income (ttm) 7.71B
EPS (ttm) N/A
PE Ratio 17.43
Forward PE 17.26
Profit Margin 20.98%
Debt to Equity Ratio 6.24
Volume 3,622,200
Avg Vol 2,706,074
Day's Range N/A - N/A
Shares Out 539.71M
Stochastic %K 79%
Beta 0.41
Analysts Sell
Price Target $362.00

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
AndrewLumpkin687
AndrewLumpkin687 Aug. 5 at 9:17 AM
$PEPE $NB $SSPC $VST $AMGN PEPE remains a community-driven meme coin, NB remains execution-driven, SSPC remains speculative, Vistra benefits from rising electricity demand, and Amgen continues advancing biotechnology innovation.
0 · Reply
CarolMontpas851
CarolMontpas851 Aug. 5 at 9:15 AM
$IBM $SAP $NVO $AMGN $SAN IBM expands enterprise AI and hybrid cloud, SAP leads enterprise software, Novo Nordisk dominates obesity treatments, Amgen advances biotechnology, and Banco Santander benefits from international banking.
0 · Reply
TinaHendren762
TinaHendren762 Aug. 5 at 8:12 AM
$PEPE $NB $SSPC $VST $AMGN PEPE remains a community-driven meme coin, NB remains execution-driven, SSPC remains speculative, Vistra benefits from rising electricity demand, and Amgen continues advancing biotechnology innovation.
0 · Reply
Jdstoner30
Jdstoner30 Aug. 5 at 6:27 AM
0 · Reply
Bretm50
Bretm50 Aug. 5 at 6:06 AM
$SLS $IBRX $PFE $MRK $AMGN Finally a well deserved piece from ST News
1 · Reply
TammyWilliams285
TammyWilliams285 Aug. 5 at 5:22 AM
$IBM $SAP $NVO $AMGN $SAN IBM expands enterprise AI and hybrid cloud, SAP leads enterprise software, Novo Nordisk dominates obesity treatments, Amgen advances biotechnology, and Banco Santander benefits from international banking.
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 5 at 5:17 AM
Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive $SLS $IBRX $PFE $MRK $AMGN https://stocktwits.com/news/equity/markets/pfizer-merck-amgen-cancer-takeover-buzz-sls-ibrx-overdrive/cZo4hyhRJ4w
3 · Reply
EarningsInsider
EarningsInsider Aug. 4 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-8-4-amgen-inc-stock/ $AMGN Amgen Earnings Transcript
0 · Reply
JenniferBeck355
JenniferBeck355 Aug. 4 at 9:05 PM
Repatha volume growth continues to anchor the top-line story for $AMGN. It’s not just new patient starts — script data (TRx) shows cardiologists deepening usage across broader practice panels as payer access friction eases.
0 · Reply
focafoca99
focafoca99 Aug. 4 at 8:21 PM
$AMGN released its Q2 2026 earnings, highlighting non-GAAP results and free cash flow.
0 · Reply
Latest News on AMGN
Amgen Earnings Call Transcript: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 hours ago

Amgen Earnings Call Transcript: Q2 2026


Amgen Earnings release: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 hours ago

Amgen Earnings release: Q2 2026


Amgen Slides: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 hours ago

Amgen Slides: Q2 2026


Amgen Quarterly report: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 hours ago

Amgen Quarterly report: Q2 2026


Amgen reports Q2 adjusted EPS $6.29, consensus $5.62

2026-08-04T20:07:12.000Z - 14 hours ago

Amgen reports Q2 adjusted EPS $6.29, consensus $5.62


Amgen second-quarter sales rise 9%, profit tops Street view

Aug 4, 2026, 4:04 PM EDT - 14 hours ago

Amgen second-quarter sales rise 9%, profit tops Street view


AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Aug 4, 2026, 4:01 PM EDT - 14 hours ago

AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS


AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND

Jul 30, 2026, 4:01 PM EDT - 5 days ago

AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND


Amgen price target raised to $360 from $350 at Barclays

2026-07-29T09:10:53.000Z - 7 days ago

Amgen price target raised to $360 from $350 at Barclays


Amgen price target raised to $420 from $400 at UBS

2026-07-13T16:35:37.000Z - 22 days ago

Amgen price target raised to $420 from $400 at UBS


Amgen price target raised to $312 from $307 at BofA

2026-07-13T11:20:20.000Z - 22 days ago

Amgen price target raised to $312 from $307 at BofA


Amgen price target raised to $343 from $340 at Guggenheim

2026-07-13T11:06:23.000Z - 22 days ago

Amgen price target raised to $343 from $340 at Guggenheim


Amgen price target raised to $340 from $327 at Truist

2026-07-07T13:16:42.000Z - 4 weeks ago

Amgen price target raised to $340 from $327 at Truist


Trial used to approve Amgen’s Tavneos retracted from NEJM

2026-06-29T19:30:10.000Z - 5 weeks ago

Trial used to approve Amgen’s Tavneos retracted from NEJM


The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 6 weeks ago

The Healthcare M&A Wave

ABT ALNY AMRX ANTX AZN BDX BEAM


Amgen price target raised to $303 from $295 at Mizuho

2026-06-16T11:15:43.000Z - 7 weeks ago

Amgen price target raised to $303 from $295 at Mizuho


Amgen taps research firm to reassess Tavneos data

Jun 11, 2026, 7:28 PM EDT - 7 weeks ago

Amgen taps research firm to reassess Tavneos data


Amgen price target raised to $340 from $332 at Morgan Stanley

2026-06-10T12:00:44.000Z - 7 weeks ago

Amgen price target raised to $340 from $332 at Morgan Stanley


Amgen Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 9:55 AM EDT - 2 months ago

Amgen Transcript: Jefferies Global Healthcare Conference 2026


AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

May 29, 2026, 4:01 PM EDT - 2 months ago

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE


This Boring Income Portfolio Strategy Could Unlock 300%+ Upside

May 27, 2026, 11:45 AM EDT - 2 months ago

This Boring Income Portfolio Strategy Could Unlock 300%+ Upside

V


Amgen Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Amgen Earnings Call Transcript: Q1 2026


Amgen Slides: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Amgen Slides: Q1 2026


Amgen Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Amgen Earnings release: Q1 2026


Amgen Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Amgen Quarterly report: Q1 2026


Amgen Posts Higher First-Quarter Profit, Revenue

Apr 30, 2026, 4:19 PM EDT - 3 months ago

Amgen Posts Higher First-Quarter Profit, Revenue


AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Apr 30, 2026, 4:01 PM EDT - 3 months ago

AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS


FDA proposes to withdraw Amgen's rare autoimmune disease drug

Apr 27, 2026, 9:04 PM EDT - 3 months ago

FDA proposes to withdraw Amgen's rare autoimmune disease drug


AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS

Apr 24, 2026, 4:01 PM EDT - 3 months ago

AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS


Amgen Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Amgen Proxy statement: Proxy filing


Amgen Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 3 months ago

Amgen Proxy statement: Proxy filing


Amgen's lung cancer drug tarlatamab wins China approval

Apr 10, 2026, 4:10 AM EDT - 4 months ago

Amgen's lung cancer drug tarlatamab wins China approval


FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths

Mar 31, 2026, 11:16 AM EDT - 4 months ago

FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths


AndrewLumpkin687
AndrewLumpkin687 Aug. 5 at 9:17 AM
$PEPE $NB $SSPC $VST $AMGN PEPE remains a community-driven meme coin, NB remains execution-driven, SSPC remains speculative, Vistra benefits from rising electricity demand, and Amgen continues advancing biotechnology innovation.
0 · Reply
CarolMontpas851
CarolMontpas851 Aug. 5 at 9:15 AM
$IBM $SAP $NVO $AMGN $SAN IBM expands enterprise AI and hybrid cloud, SAP leads enterprise software, Novo Nordisk dominates obesity treatments, Amgen advances biotechnology, and Banco Santander benefits from international banking.
0 · Reply
TinaHendren762
TinaHendren762 Aug. 5 at 8:12 AM
$PEPE $NB $SSPC $VST $AMGN PEPE remains a community-driven meme coin, NB remains execution-driven, SSPC remains speculative, Vistra benefits from rising electricity demand, and Amgen continues advancing biotechnology innovation.
0 · Reply
Jdstoner30
Jdstoner30 Aug. 5 at 6:27 AM
0 · Reply
Bretm50
Bretm50 Aug. 5 at 6:06 AM
$SLS $IBRX $PFE $MRK $AMGN Finally a well deserved piece from ST News
1 · Reply
TammyWilliams285
TammyWilliams285 Aug. 5 at 5:22 AM
$IBM $SAP $NVO $AMGN $SAN IBM expands enterprise AI and hybrid cloud, SAP leads enterprise software, Novo Nordisk dominates obesity treatments, Amgen advances biotechnology, and Banco Santander benefits from international banking.
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 5 at 5:17 AM
Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive $SLS $IBRX $PFE $MRK $AMGN https://stocktwits.com/news/equity/markets/pfizer-merck-amgen-cancer-takeover-buzz-sls-ibrx-overdrive/cZo4hyhRJ4w
3 · Reply
EarningsInsider
EarningsInsider Aug. 4 at 9:47 PM
https://www.marketbeat.com/earnings/reports/2026-8-4-amgen-inc-stock/ $AMGN Amgen Earnings Transcript
0 · Reply
JenniferBeck355
JenniferBeck355 Aug. 4 at 9:05 PM
Repatha volume growth continues to anchor the top-line story for $AMGN. It’s not just new patient starts — script data (TRx) shows cardiologists deepening usage across broader practice panels as payer access friction eases.
0 · Reply
focafoca99
focafoca99 Aug. 4 at 8:21 PM
$AMGN released its Q2 2026 earnings, highlighting non-GAAP results and free cash flow.
0 · Reply
Hihosilveraway11
Hihosilveraway11 Aug. 4 at 8:15 PM
$AMGN the news is gooooood!
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 4 at 8:12 PM
$AMGN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $4.40 up 65.41% YoY • Reported revenue of $10.05B up 9.53% YoY • For the full year 2026, Amgen expects total revenues in the range of $38.2 billion to $39.4 billion, GAAP EPS of $15.80 to $17.08, and non-GAAP EPS of $22.30 to $23.50.
0 · Reply
profit_guru
profit_guru Aug. 4 at 8:08 PM
$AMGN - expect sell the news tomorrow…near term 360…imo
1 · Reply
judgeyoung2
judgeyoung2 Aug. 4 at 8:04 PM
$AMGN get calls tomorrow after the iv crushes. it’s about to breakout.
1 · Reply
Cutlass
Cutlass Aug. 4 at 8:03 PM
$AMGN Nice 👀
1 · Reply
Hihosilveraway11
Hihosilveraway11 Aug. 4 at 6:53 PM
$AMGN talking favorably on AMGN on Fox Biz
0 · Reply
DefenseMania
DefenseMania Aug. 4 at 6:45 PM
$AMGN Breaks $400 then we get a 4-1 split
0 · Reply
Ziggy11
Ziggy11 Aug. 4 at 6:40 PM
$BKNG $ANET $ALAB $AMGN $UPST Winners ? after the bell.
0 · Reply
DefenseMania
DefenseMania Aug. 4 at 6:39 PM
$AMGN $GILD expecting some good reports AH 🚀🚀🚀as well as $KTOS
0 · Reply
27R
27R Aug. 4 at 4:36 PM
$AMGN Buckle up — earnings after the close today.
0 · Reply
Estimize
Estimize Aug. 4 at 3:01 PM
$AMGN reports after the close, Estimize Consensus +0.11 EPS and +98.71M Revs compared to WS http://www.estimize.com/amgn/fq2-2026?utm_conte
0 · Reply
11thestate
11thestate Aug. 4 at 1:22 PM
Everything You Need to Know About the $69M $CCXI / $AMGN Settlement Payout Q: What happened? A: ChemoCentryx was accused of misleading investors about the effectiveness and safety of its experimental drug avacopan, as well as the strength of the ADVOCATE clinical trial. When FDA documents revealed concerns about the trial and the drug's safety, the stock dropped sharply, and investors filed a lawsuit. Q: Am I actually eligible? A: If you bought $CCXI shares between 2019, and 2021, you're likely eligible. You don't need to still own the stock to file a claim past losses count Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. The exact timing depends on the court and settlement administration. Check if you're eligible and file your claim before the deadline: https://11th.com/cases/chemocentryx-investor-settlement
0 · Reply